Related by context. All words. (Click for frequent words.) 73 Secondary endpoints include 70 Secondary endpoints included 69 CINQUIL 69 glycosylated hemoglobin levels 68 demonstrated statistically significant 68 morphometric vertebral fractures 68 ACTEMRA TM 67 certolizumab 67 Pharmacokinetic parameters 67 RoACTEMRA 67 Primary endpoints 67 hematological parameters 67 Zemplar Capsules 66 relapsed MM 66 PASI scores 66 hemodynamic measurements 66 intravascular hemolysis 66 Crohn Disease Activity 66 demonstrated antitumor activity 66 MoxDuo TM IR 66 pharmacodynamic PD 66 urinary N telopeptide 66 clevidipine 65 alicaforsen enema 65 pain palliation 65 CIMZIA R 65 serum urate 65 Severity Index PASI 65 CIMZIA TM certolizumab pegol 65 analgesic efficacy 65 pharmacodynamic parameters 65 teriflunomide 65 preclinical efficacy 65 tipranavir r 65 epoetin alpha 65 oral rivaroxaban 65 Platinol ® cisplatin 65 REMINYL ® 65 glycosylated hemoglobin HbA1c 64 haematologic 64 pharmacokinetic PK 64 lumbar spine bone 64 ADCS CGIC 64 cardiac perfusion 64 prospectively stratified 64 Secondary efficacy endpoints 64 galiximab 64 Symptom severity 64 lumbar spine BMD 64 WOMAC pain 64 oral levofloxacin 64 mean ± SEM 64 VIAject ™ 64 ADAS cog 64 vidofludimus 64 Meta analyzes 64 EDARBI 64 venous thromboembolic disease 64 β blockers 64 XIENCE V PROMUS Stent 64 antiarrhythmic drug 64 inhaled iloprost 64 MGN# 64 tolerability profiles 64 Xelox 64 intermittent dosing 64 BARACLUDE r 64 paricalcitol 64 hematologic parameters 63 Pharmacodynamic 63 fosbretabulin 63 basal bolus regimen 63 somatostatin analog 63 Ceplene/IL-2 63 CYT# potent vascular disrupting 63 Randomized Evaluation 63 melphalan prednisone 63 tapentadol ER 63 HAQ DI 63 microbiological eradication 63 8mg/kg 63 Tasigna prolongs 63 CIMZIA ™ 63 MoxDuo 63 Psoriasis Area 63 doxorubicin cyclophosphamide 63 corticosteroid dose 63 VELCADE melphalan 63 achieved statistical significance 63 liver histology 63 Novo TTF 63 ACR# ACR# 63 Index CDAI 63 DLQI 63 symptomatic VTE 63 HDL Selective Delipidation 63 paclitaxel eluting stents 63 Perforomist ™ Inhalation Solution 63 Vascugel ® 63 Capesaris 63 desvenlafaxine succinate 63 canakinumab 63 oral FTY# 63 ibandronate 63 hyperphenylalaninemia HPA due 63 serum phosphorous 63 Histologic 63 INTEGRILIN R eptifibatide Injection 63 hypofractionated 63 angiotensin analog 63 endoscopic remission 63 acyclovir Lauriad R 63 Randomized controlled 63 oral ibandronate 63 reactogenicity 63 Secondary endpoints 63 esophagogastric 63 catheter occlusion 63 intradermal injections 63 neurologic progression 63 Free Survival PFS 63 CIMZIA TM 63 SPRYCEL ® 62 pharmacokinetic profiles 62 AGILECT R 62 BENICAR HCT 62 everolimus eluting stents 62 olanzapine LAI 62 abacavir lamivudine 62 CHAMPION PCI 62 ® bortezomib 62 oral antidiabetic medication 62 colorectal adenoma 62 nonrandomized 62 colesevelam HCl 62 sargramostim 62 AGILECT ® 62 mg QD 62 mg/m2 cohort 62 HuMax EGFr 62 HIV HCV coinfected 62 oxycodone CR 62 RE LY ® 62 ADAS Cog 62 liposome formulation 62 PSADT 62 pharmacodynamics PD 62 administered subcutaneously 62 strontium ranelate 62 Cimzia TM 62 SELENA SLEDAI 62 TLUS 62 non squamous histology 62 left ventricular diastolic 62 TAXUS Liberté stent 62 #mg/day [001] 62 pramlintide metreleptin combination 62 zoledronate 62 evaluating REVLIMID 62 unfractionated heparin UFH 62 salmeterol fluticasone 62 weekly subcutaneous injections 62 Fibromyalgia Impact Questionnaire 62 echocardiographic parameters 62 Brief Psychiatric 62 NPH insulin 62 pharmacokinetic PK profile 62 CTAP# Capsules 62 percutaneous vertebroplasty 62 tolterodine ER 62 trials RCTs 62 APTIVUS 62 Pegasys ® 62 cinacalcet 62 DAS# remission 62 tolvaptan 62 PI3K/Akt pathway inhibitor 62 RECORD1 62 headache nasopharyngitis 62 NSABP C 62 Cardiotoxicity 62 DASISION 62 virologic responses 62 radiotherapy RT 62 fasting plasma glucose FPG 62 TAXUS Express Stent 62 paclitaxel poliglumex 62 ARB telmisartan 62 electrophysiologic 62 symptomatic paroxysmal AF 62 Pharmacokinetic 62 GAMMAGARD 62 Phase 1a clinical 62 mucosal healing 62 darunavir r 62 deep venous thromboses 62 dosage regimens 62 antiretroviral naïve 62 Q#IR 62 achieved ACR# 62 icatibant 62 evaluating tivozanib 62 evaluating mipomersen 62 Vaxfectin R 62 ULORIC 62 Omacetaxine mepesuccinate 62 albiglutide 62 plus methotrexate 62 platelet reactivity 62 ARCALYST ® 62 PCWP 62 interferon ribavirin 62 oral picoplatin 62 exploratory endpoints 62 SERCA2a 62 adalimumab 62 prospective multicentre 62 methotrexate monotherapy 62 Vascugel R 62 bortezomib refractory 62 CRLX# 62 APTIVUS r 62 reduce serum phosphate 62 achieved CCyR 62 Virulizin ® 62 FOLPI 62 ispinesib administered 62 Cypher Stent 61 intact parathyroid hormone 61 fludarabine cyclophosphamide 61 SIMPADICO 61 Erythropoietic therapies may 61 pharmacokinetics PK 61 AST ALT 61 O PPDS 61 linaclotide treated 61 urodynamic 61 insulin glargine rDNA origin 61 pulmonary exacerbations 61 NP2 Enkephalin 61 CANCIDAS 61 XIENCE V demonstrated 61 Xanafide 61 postoperative AF 61 ZOLINZA 61 nicardipine 61 Aptivus ® 61 DAS# scores 61 receiving VELCADE 61 GOUT 61 lipid parameters 61 concurrent chemoradiation 61 r hGH 61 colorectal liver metastases 61 serologically active patients 61 peak VO2 61 pharmacokinetic characteristics 61 Cardiorespiratory fitness 61 Teriflunomide 61 eNO 61 TAXUS ATLAS 61 antiviral efficacy 61 worsening thrombocytopenia 61 prespecified secondary 61 serum phosphate 61 ancrod 61 4mg/kg 61 QTcF 61 novel VDA molecule 61 MEND CABG 61 dosing cohort 61 mineral density BMD 61 EQ 5D 61 Protelos 61 ratio ICER 61 viral kinetics 61 ascending dose 61 L PPDS 61 secondary efficacy endpoints 61 TURBT 61 Golimumab 61 Diamondback #deg 61 Pharmacokinetics PK 61 Montgomery Asberg Depression 61 VBLOC TM 61 dipyridamole plus 61 HBeAg seroconversion 61 adenoma recurrence 61 CLARITY study 61 velafermin 61 BEXXAR Therapeutic Regimen 61 Vildagliptin 61 bronchial hyperresponsiveness 61 Targretin capsules 61 CCyR 61 pyridostigmine 61 subcutaneously administered 61 prednisone prednisolone plus 61 IFN α 61 plus prednisone prednisolone 61 CIPN 61 CHOP chemotherapy 61 brachial artery flow 61 abdominal pain abdominal discomfort 61 efficacy tolerability 61 plus COPEGUS 61 tapentadol IR 61 CRMD# 61 mitoxantrone plus 61 Tiotropium 61 carotid artery stenting CAS 61 NEUVENGE 61 liposomal formulation 61 interferon alfa 2b 61 NAVISTAR R 61 FOSRENOL ® 61 STRIDE PD 61 SUSTENNA TM 61 divalproex sodium 61 dimeglumine 61 progression TTP 61 golimumab CNTO 61 kidney urologic 61 sacral nerve stimulation 61 Myocardial Infarction Study 61 pharmacokinetic pharmacodynamic 61 clinically meaningful improvements 61 fructosamine 61 peginterferon alfa 2a #KD 61 Achieves Primary Endpoint 61 Demonstrates Positive 61 SBM frequency 61 Ophena TM 61 orthostatic blood 61 aplindore 61 UPDRS scores 61 Fracture Intervention Trial 61 intra articular injections 61 #μg [002] 61 maximally tolerated dose 61 aspirin clopidogrel 61 Certolizumab pegol 61 CNS LS 61 BPH symptom 61 hepatic arterial 61 recurrent malignant glioma 61 6MWD 61 Echocardiographic 61 pharmacodynamic effects 61 cystinosis patients 61 Non inferiority 61 PSA nadir 61 serum HBV DNA 60 prospectively defined 60 blood Phe levels 60 Teriparatide 60 Randomised 60 intravenous cyclophosphamide 60 dosing frequency 60 nasal symptom 60 FDA defined valvulopathy 60 SVR# 60 radiochemotherapy 60 antiretroviral naive 60 spontaneous bowel movements 60 oral diclofenac 60 ATACAND 60 TWYNSTA 60 dose proportionality 60 resected pancreatic cancer 60 liver transaminases 60 TPV r 60 treatment naive genotype 60 Hsp# Inhibitor 60 ritonavir boosted 60 FUSILEV enhances 60 intravenous dosing 60 Intravitreal 60 Initiated Phase 60 p# inhibitor 60 MoxDuo IR 60 interobserver 60 corrected QT interval 60 plus prednisone 60 GEM OS2 60 Transcatheter aortic valve implantation 60 plus MTX 60 relapsing remitting MS RRMS 60 AERx ® 60 Insulin PH# 60 BrachySil TM 60 intracoronary 60 Perforomist Inhalation Solution 60 SYMBICORT pMDI 60 EGS# 60 MAGE A3 ASCI 60 antiplatelet medications 60 CYP#D# inhibitor 60 NEVO ™ 60 FDG-PET/CT 60 cisplatin gemcitabine 60 VBLOC ® 60 hepatic insufficiency 60 recurrent genital herpes 60 Scale EDSS 60 NLX P# 60 Major Adverse Cardiac 60 genotypic resistance 60 Solid Tumors criteria 60 Proellex TM 60 Unified Parkinson Disease 60 Long Lesion 60 HCV RESPOND 2 60 clinically meaningful 60 dose pravastatin 60 intratumoral 60 certolizumab pegol 60 Angiographic 60 sUA 60 alteplase 60 azilsartan medoxomil 60 biliary tract cancer 60 MVA MUC1 IL2 60 naïve HCV 60 prospective multicenter study 60 tissue oxygenation 60 ER CHOP 60 Orthokine 60 CRp 60 Alequel ™ 60 tumor histology 60 BRIM2 60 torsemide ER 60 GORE VIABAHN Endoprosthesis 60 ORENCIA R 60 mild hepatic impairment 60 6R BH4 60 undergoing elective percutaneous 60 clinical meaningfulness 60 Betaferon R 60 Bivalirudin 60 #dhTxB# 60 CPAP adherence 60 Afatinib 60 linear pharmacokinetics 60 pyrimidine nucleoside analog 60 GH deficiency 60 estramustine 60 PEG interferon 60 Panzem R NCD 60 HOMA IR 60 Antisoma AS# 60 Aeolus Pharmaceuticals Announces 60 mg administered orally 60 Active Ulcerative Colitis 60 guanfacine extended release 60 IntroductionThe 60 bioprosthetic valve 60 lispro 60 WOMAC scores 60 pulmonary artery banding 60 ADCS ADL 60 ARIXTRA 60 rosuvastatin #mg 60 zonisamide SR 60 APPRAISE 60 binary restenosis 60 RAPTIVA 60 Coronary CTA 60 INCB# [001] 60 refractory colorectal cancer 60 Demonstrate Significant 60 paliperidone ER 60 LEXIVA r 60 undetectable HBV DNA 60 mg BID 60 trough FEV1 60 acromegalic patients 60 spirometric 60 tocilizumab 60 subcutaneous dosing 60 riociguat 60 TUMT 60 pharmacodynamic properties 60 RECIST Response Evaluation Criteria 60 NSTE ACS 60 platinum chromium PROMUS 60 plus octreotide LAR 60 radiographic outcomes 60 mg TID 60 dose proportional pharmacokinetics 60 Hematologic 60 lactate dehydrogenase LDH 60 retinal thickness 60 oral anticoagulant therapy 60 YMRS 60 oral prodrug 60 serum lipid 60 MERIT ES 60 Oral NKTR 60 Daptomycin 60 HGS ETR2 60 Shows Statistically Significant 60 indicates cardio circulatory 60 Acute Ischemic Stroke 60 Thrombolysis 60 Catena ® 60 Adalimumab 60 salmeterol fluticasone propionate 60 EMBLEM TM 60 aspartate aminotransferase AST 60 novel histone deacetylase 60 ACR# response 60 oral anticoagulation 60 Tolerability 60 topical NSAIDs 60 postprandial blood glucose 60 lanthanum carbonate 60 TAXUS VI 60 oral prednisolone 60 transdermal estradiol 60 receiving XGEVA 60 pegylated alpha interferon 60 NIHSS 59 Bayer HealthCare Onyx Pharmaceuticals 59 BoNTA 59 HER2 expression 59 decitabine 59 KAPIDEX 59 angiographic outcomes 59 Intravenous immunoglobulin 59 triglyceride concentrations 59 plasma pharmacokinetics 59 TNF Tumor Necrosis Factor 59 mg hydrochlorothiazide 59 forodesine 59 conventional DMARDs 59 multicenter randomized placebo controlled 59 pharmacokinetic parameters 59 EURIDIS 59 CYP#A# substrate 59 SYNERGY Stent 59 SPIRIT FIRST 59 Apoptone 59 subcutaneous SC 59 metastatic colorectal carcinoma 59 Coronary Artery Bypass Graft 59 null responder 59 DAS# CRP 59 visilizumab 59 Alzheimer Disease Assessment 59 hA# 59 taxane resistant 59 steroid dexamethasone 59 Natalizumab 59 inflammatory biomarkers 59 antitumor efficacy 59 Warfarin Coumadin 59 dalteparin 59 serum phosphate levels 59 Rigorous scientific 59 virologic response 59 myocardial reperfusion 59 leukotriene receptor antagonist 59 postintervention 59 metastatic neuroendocrine tumors 59 randomized blinded 59 Decitabine 59 prucalopride 59 ALA PDT 59 anti arrhythmic drug 59 relapsing multiple sclerosis 59 DAVANAT R exhibits 59 immune modulating 59 Androxal TM 59 ascending aortic 59 SF #v# 59 imatinib therapy 59 briakinumab 59 TO AVOID PREGNANCY WHILE 59 pulmonary toxicity 59 MEND CABG II 59 dyssynchrony 59 GERD symptom 59 plasma creatinine 59 BeneFIX 59 fluticasone salmeterol 59 PEGPH# 59 IMPACT DCM 59 xanthine oxidase inhibitor 59 IOP lowering 59 pharmacodynamic profiles 59 oral renin inhibitor 59 AVONEX PEN 59 FFR measurements 59 dose Iluvien 59 ketorolac 59 somatostatin analogues 59 Visual Analogue Scale VAS 59 mGluR5 NAM 59 moderate renal impairment 59 multivariate Cox 59 microbiologically evaluable 59 unfavorable cytogenetics 59 Hematologic toxicity 59 APTIVUS R 59 pretreatment serum 59 alfa 2a 59 doxorubicin docetaxel 59 eculizumab therapy 59 ALSFRS R 59 HORIZONS AMI trial 59 aldosterone antagonists 59 Helicobacter pylori eradication 59 LEVAQUIN ® 59 INVEGA ® 59 prospective randomized controlled 59 disease progression TTP 59 Pivotal Phase III 59 miconazole Lauriad ® 59 SCIg 59 PTNS 59 zoledronic acid Reclast 59 ADAGIO study 59 hemodialysis patients 59 adjuvant GIST 59 brain tumor resection 59 Carotid endarterectomy 59 tumor progression TTP 59 pegylated interferon alfa 59 Symbicort SMART 59 recombinant PSMA vaccine 59 brand ciclesonide HFA 59 ESBA# 59 incidence ≥ 59 HGS ETR1 mapatumumab 59 VTE prophylaxis 59 tiotropium 59 fasting plasma glucose 59 prespecified 59 statistically significant efficacy 59 hip BMD 59 statistically significant p = 59 ara C 59 crizotinib PF # 59 response CCyR 59 mg kg BID 59 Zometa hazard 59 NSABP B 59 Novolimus 59 NYHA functional class 59 Pitavastatin 59 Neuropsychiatric Inventory NPI 59 death reinfarction 59 oral talactoferrin 59 severe exacerbations 59 IONSYS TM 59 CYT# QbG# 59 DAPT 59 docetaxel Taxotere ® 59 confirmatory clinical 59 Ocular Surface Disease 59 im peramivir 59 UPDRS 59 PANSS 59 F FDG PET 59 pharmacodynamic markers 59 multicentre randomized 59 haemodynamic 59 FOLFOX6 59 MYCAMINE 59 AA Amyloidosis 59 phase IIb study 59 intratympanic 59 secondary endpoint 59 Vidofludimus 59 peptide conjugated 59 serum triglycerides 59 #mg/m# [001] 59 Thalomid ® 59 budesonide formoterol 59 GnRH agonist 59 EXPAREL ™ 59 UPDRS Part III 59 erection hardness 59 ARIKACE 59 Thrombotic thromboembolic complications 59 serum lipid levels 59 Relapsed Multiple Myeloma 59 HDRS 59 acamprosate calcium 59 ABSORB trial 59 ACZ# 59 Biphasic 59 TAXOTERE R 59 lenalidomide Revlimid R 59 follicular lymphoma FL 59 MP4OX 59 dacarbazine chemotherapy 59 PRESEPT study 59 RE SURGE 59 infliximab monotherapy 59 Tumor Response 59 systemic immunosuppressive drugs 59 ALB # 59 #mg BID [001] 59 macrolide antibiotic 59 assessing T DM1 59 caspofungin 59 extrapyramidal symptoms 59 TMC# r 59 Val HeFT 59 metaglidasen 59 recurrent glioblastoma multiforme 59 Demonstrates Significant 59 relapsed myeloma 59 tamoxifen Nolvadex ® 59 CorVue ™ 59 Randomized clinical trials 59 rituximab Rituxan 59 CYP#A# CYP#D# 59 IIa trials 59 convenient dosing regimen 59 BRIM3 59 receiving golimumab 59 Flu Cy 59 serum ALT 59 eszopiclone 59 erlotinib Tarceva ® 59 florbetaben 59 treatment naïve genotype 59 BOLDER II 59 #mg/day [002] 59 clinicopathological 59 metabolic parameters 59 LymphoStat B belimumab 59 HCD# [002] 59 Multivariate logistic regression 59 Zevalin consolidation 59 acute postoperative 59 5 Fluorouracil 59 Hypertrophy 59 avosentan 59 Edge STudy 59 locoregional 59 Scale PANSS 59 Forodesine HCl 59 BENICAR 59 Plaque Psoriasis 59 timepoints 59 chemoradiotherapy 59 multicenter prospective 59 antithrombotics 59 baminercept 59 sitaxsentan 59 metformin monotherapy 59 NOXAFIL Oral Suspension 59 antiangiogenic agent 59 prospective multicenter randomized 59 FOLFOX6 chemotherapy regimen 59 viral tropism 59 VBLOC R 59 pharmacokinetic PK study 59 SSRI citalopram 59 chemoradiation therapy 59 interferon beta therapy 59 blinded randomized placebo controlled 59 multicenter randomized controlled 59 intima media thickness IMT 59 COMFORT II 59 pulmonary capillary wedge 59 PD LID 59 Cardiopulmonary bypass 59 QTc 59 ribavirin RBV 59 sirolimus eluting stents 59 daily subcutaneous injections 59 favorable pharmacokinetic profile 59 Pemetrexed 59 NIS LL 59 hip resurfacing arthroplasty 59 gemcitabine carboplatin 59 cediranib 59 radezolid 59 cyclophosphamide doxorubicin vincristine 59 posttreatment 58 TRX1 58 clinico pathological 58 follicular NHL 58 inhaled budesonide 58 cobiprostone 58 naltrexone SR 58 surgical prophylaxis 58 gemtuzumab ozogamicin 58 hindfoot 58 meta regression 58 secondary efficacy endpoint 58 titrated glipizide 58 Demonstrates Sustained 58 LDB CPR 58 PEG IFN 58 Dabigatran etexilate 58 sustained virological response 58 zotarolimus 58 oncologic outcomes 58 Prospective Randomized 58 TYGACIL 58 anthropometric measures 58 moderate hepatic impairment 58 hepatic fibrosis 58 N telopeptide 58 subcutaneous PRO 58 immunosuppressive regimen 58 #mg/m# [002] 58 Fidaxomicin 58 Mantel Haenszel 58 MGd 58 CARE HF 58 YONDELIS 58 rhIGF-I/rhIGFBP-3 58 Severity MSCS score 58 serum PTH 58 #mg QD [002] 58 direct thrombin inhibitors 58 Dasatinib 58 daunorubicin 58 papillary renal cell carcinoma 58 recurrent GBM 58 analgesic medications 58 ACE Inhibitor 58 huN# DM1 58 Ziprasidone 58 thetreatment 58 Virologic 58 postoperative chemotherapy 58 scintigraphic 58 IV bolus 58 Degarelix 58 Randomized trials 58 erythropoietic 58 Xeloda ® 58 clinically meaningful reductions 58 subthreshold depression 58 RG# synthetic human 58 MitraClip device 58 carotid endarterectomy CEA 58 NIH CPSI 58 saline placebo 58 serum calcium levels 58 T2DM 58 esophageal carcinoma 58 Events MACE 58 Triapine 58 AZX# 58 delafloxacin 58 cerebral oximetry 58 topical diclofenac 58 GERD migraine headaches 58 attain statistical significance 58 therapeutic regimens 58 dose cytarabine 58 nonvertebral 58 tacrolimus ointment 58 Bezielle 58 gadolinium enhancing lesions 58 Omiganan 58 hemodynamic parameters 58 humanized therapeutic 58 paraprotein 58 ACE inhibitor ramipril 58 serum cortisol 58 buprenorphine naloxone 58 preclinical pharmacokinetic 58 hemoglobin A1c levels 58 perioperative mortality 58 risedronate 58 LCP AtorFen 58 serum clusterin levels 58 lesional 58 TAXUS Stent 58 ropivacaine 58 Long Term Efficacy 58 endothelin antagonists 58 Pegylated Interferon 58 BARACLUDE ® 58 prospectively evaluated 58 pimecrolimus cream 58 CAELYX 58 bi ventricular pacing 58 Drug eluting stent 58 baseline LDH 58 Y BOCS 58 flibanserin #mg 58 USL# 58 CCR9 antagonist 58 Subgroup analyzes 58 Primary Endpoint 58 albumin excretion rate 58 thalidomide Thalomid 58 hMG 58 dosimetric 58 unresectable HCC 58 mitral annular 58 CTEPH 58 antiangiogenic therapy 58 recombinant interferon 58 CaPre TM 58 Candesartan 58 3D conformal radiation 58 Cloretazine R VNP#M 58 mitral regurgitation MR 58 XOPENEX Inhalation Solution 58 UPLYSO 58 Bosutinib 58 PANSS total 58 plasma uric acid 58 Moxifloxacin 58 postprocedure 58 NeuroSTAT ® 58 ritonavir boosted protease inhibitor 58 Aridol TM 58 hypogonadal men 58 alanine aminotransferase ALT 58 standard chemotherapy regimen 58 Unstable Angina 58 postsurgical pain 58 -#.# log# copies mL 58 XL# SAR# 58 tolerability pharmacokinetics 58 blinded randomized 58 QTc intervals 58 Inventory BPI 58 Ventavis ® 58 sipuleucel T 58 gemcitabine cisplatin 58 bronchoalveolar lavage 58 trastuzumab emtansine T DM1 58 Fondaparinux 58 bronchodilatory 58 Omacetaxine 58 Temsirolimus 58 REVIVE Diabetes 58 Traficet EN 58 NMDA antagonists 58 Montgomery Åsberg Depression 58 refractory AML 58 convergent validity 58 serum aminotransferase levels 58 alfuzosin 58 enzyme immunoassay EIA 58 CRT ICD 58 LAB CGRP 58 Cognitive behavioral 58 Triapine R 58 virologic 58 stage IIIb IV 58 TROPOS 58 flurpiridaz F 58 topical gel formulation 58 statistically significant superiority 58 AZT zidovudine Retrovir 58 glycated hemoglobin HbA1c 58 Hormone Refractory Prostate Cancer 58 NATRECOR ® 58 Raptiva r 58 Ejection fraction 58 evaluating Actimmune 58 serum LDL cholesterol 58 dosing cohorts 58 placebo controlled dose escalation 58 recurrent herpes labialis 58 duplex ultrasonography 58 osteoporotic vertebral compression fractures 58 mITT population 58 Diabetic Foot Ulcer 58 Insulin detemir 58 budesonide foam 58 octreotide LAR 58 VP# [004] 58 docetaxel pretreated 58 PRIMO CABG2 58 cerebral somatic oximeter 58 serologically active systemic lupus 58 plus dexamethasone 58 boosted protease inhibitor 58 lupus renal disease 58 CTA# Injection 58 thorough QT 58 ACR# responses 58 MCyR 58 interpersonal psychotherapy 58 hemoglobin A1c HbA1c 58 neratinib 58 IV bisphosphonates 58 Evoltra ® 58 UPDRS motor 58 activated partial thromboplastin 58 Peg riba 58 postoperative inflammation